BOLERO-2 - will this change practice in advanced breast cancer?

This number will be updated

Future of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?

Triple negative breast cancer (TNBC): challenges and solutions via the immune cells TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates...

COPD heterogeneity: what this will mean in practice.

COPD is a complex collection of conditions. All share the feature of limited expiratory air flow. It is a "disease" in the same sense as is "chronic renal failure." Like most other chronic organ failure "diseases," COPD has disparate causes, and patients are heterogeneous in their prognosis and response to treatment. Unlike many other diseases, the heterogeneity of COPD is just beginning to be ...

Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice

The systemic therapeutic management of breast cancer has undergone significant transformation in the past decade. Without targeted therapies, conventional treatment with cytotoxic agents has reached the limit of its potential in terms of patient survival for most types of cancer. Enhanced understanding of the pathogenesis of tumor cell growth and metastasis has led to the identification of sign...

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

BACKGROUND The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR(+)), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors (NSAIs). The overall survival (OS) anal...